Linda Morrow

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal et al. · Gastroenterology · 2013 · 906 citations

Metabolic Syndrome, Hepatology, Nonalcoholic Fatty Liver Disease +9

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula et al. · Diabetes Care · 2013 · 281 citations · Full text

Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes

Alan C. Moses, Simon C. Young, Linda Morrow et al. · Diabetes · 1996 · 281 citations

Improves Glycemic Control, Immunology, Type Ii +19

Comorbid Illness is Associated with Survival and Length of Hospital Stay in Patients with Chronic Disability

Paula A. Rochon, Jeffrey N. Katz, Linda Morrow et al. · Medical Care · 1996 · 270 citations

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

Damayanthi Devineni, Linda Morrow, Marcus Hompesch et al. · Diabetes Obesity and Metabolism · 2012 · 221 citations